Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldman

Showing results (181-190 of 304) with videos related to

Pageof 31
Sort By:
Frontiers in Oncology|December 19, 2019
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung CancerJonathan W Goldman, David M Waterhouse, Ben George, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2015
Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerJohanna C Bendell, Lee S Rosen, Robert J Mayer, et al.
Frontiers in Physiology|September 9, 2015
Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient's autoregulatory capacity?Alyssa W Goldman, Yvonne Burmeister, Konstantin Cesnulevicius, et al.
Drugs in R&D|December 23, 2015
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid TumorsGerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, et al.
Clinical and Experimental Rheumatology|October 19, 2021
Autoantibodies targeting LINE-1-encoded ORF1p are associated with systemic lupus erythematosus diagnosis but not disease activityBrendan Antiochos, Merlin Paz, Jessica Li, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2015
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerJohanna C Bendell, Lee S Rosen, Robert J Mayer, et al.
Frontiers in Oncology|June 5, 2023
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage Jonathan W Goldman, Lynette M Sholl, Sanja Dacic, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Scientific Reports|February 9, 2018
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancerManjima Dhar, Jessica Wong, James Che, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
Pageof 31

Showing results (181-190 of 304) with videos related to

Sort By:
Pageof 31
Frontiers in Oncology|December 19, 2019
Safety and Efficacy Results of a Phase I, Open-Label Study of Concurrent and Delayed Nivolumab in Combination With <i>nab</i>-Paclitaxel and Carboplatin in Advanced Non-small Cell Lung CancerJonathan W Goldman, David M Waterhouse, Ben George, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2015
Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerJohanna C Bendell, Lee S Rosen, Robert J Mayer, et al.
Frontiers in Physiology|September 9, 2015
Bioregulatory systems medicine: an innovative approach to integrating the science of molecular networks, inflammation, and systems biology with the patient's autoregulatory capacity?Alyssa W Goldman, Yvonne Burmeister, Konstantin Cesnulevicius, et al.
Drugs in R&D|December 23, 2015
Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid TumorsGerald S Falchook, Xiaofei Zhou, Karthik Venkatakrishnan, et al.
Clinical and Experimental Rheumatology|October 19, 2021
Autoantibodies targeting LINE-1-encoded ORF1p are associated with systemic lupus erythematosus diagnosis but not disease activityBrendan Antiochos, Merlin Paz, Jessica Li, et al.
Cancer Chemotherapy and Pharmacology|September 16, 2015
Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancerJohanna C Bendell, Lee S Rosen, Robert J Mayer, et al.
Frontiers in Oncology|June 5, 2023
Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage Jonathan W Goldman, Lynette M Sholl, Sanja Dacic, et al.
Future Oncology (London, England)|August 11, 2022
LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA <i>RET</i> fusion-positive non-small-cell lung cancerMasahiro Tsuboi, Jonathan W Goldman, Yi-Long Wu, et al.
Scientific Reports|February 9, 2018
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancerManjima Dhar, Jessica Wong, James Che, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 TrialXiuning Le, Robin Cornelissen, Marina Garassino, et al.
Pageof 31